Source comparison
Difference Between Ipamorelin and Tesamorelin + Ipamorelin Blend: Comparison Table
Receptor Target Ghrelin receptor (GHS-R1a) only GHRH receptor + ghrelin receptor (dual pathway) Blend activates complementary signalling cascades (PKA + PKC), producing non-redundant anabolic effects HGH Release Pattern Pulsatile peaks (2–3× baseline), 2-hour
This comparison does not assign a generated winner or score.
- Receptor Target
- Ghrelin receptor (GHS-R1a) only
- GHRH receptor + ghrelin receptor (dual pathway)
- Blend activates complementary signalling cascades (PKA + PKC), producing non-redundant anabolic effects
- HGH Release Pattern
- Pulsatile peaks (2–3× baseline), 2-hour duration
- Sustained elevation (tesamorelin) + pulsatile surges (ipamorelin), 16–18 hour window
- Extended HGH exposure required for VAT mobilisation and hepatic lipid oxidation
- Visceral Fat Reduction
- Minimal. Generalised lipolysis only
- 12–18% VAT reduction over 16–26 weeks
- Tesamorelin component drives VAT-specific triglyceride release; ipamorelin alone lacks this selectivity
- Lean Mass Retention
- +1.2–1.8kg over 12 weeks
- +2.0–2.5kg over 16 weeks
- Blend's dual activation sustains nitrogen balance during caloric deficit, preserving muscle protein synthesis
- Dosing Frequency
- 2–3 times daily (short half-life)
- Once daily (tesamorelin) + twice daily (ipamorelin)
- Blend requires coordinated timing but reduces total injection count vs ipamorelin monotherapy
- Side Effect Profile
- Transient water retention, mild injection-site reaction
- Similar GI tolerance; slightly higher incidence of peripheral oedema due to sustained HGH elevation
- Dual agonism does not proportionally increase cortisol or prolactin. Selectivity preserved
- Research Application
- Generalised HGH output studies, lean mass protocols
- Metabolic syndrome, visceral adiposity, lipodystrophy research
- Blend addresses cardiometabolic endpoints (waist circumference, liver fat) ipamorelin monotherapy does not target